view페이지

MedPacto, Inc. and OncoVenture have submitted IND application to US FDA for Medpacto's oral ALK5 inhibitor, TEW-7197.

Apr 03, 2014MILESTONESHit 1101

On March 25th 2014, MedPacto, Inc. and OncoVenture (NOV, Director: Dr. In-Chul Kim) have submitted an investigational new drug (IND) application to the US Food and Drug Administration (FDA) for its TEW-7197, an oral ALK5 inhibitor targeting solid tumor indications. Medpacto, Inc. a spun-off company from Theragen Etex Co to focus on developing TEW-7197. TEW-7197 had been supported by the Program for Disease-Based Discovery of Global New Drug Candidates.
 Once TEW-7197 gets an IND Approval, MedPacto, Inc./NOV will initiate a Phase I clinical study for the patients with solid tumors at three different clinical sites in the United States. Covance is the clinical CRO to help the clinical development of TEW-7197. Through the clinical development, Medpacto Inc. in collaboration with NOV will increase the value of this compound, which will be out-licensed to other pharmaceutical companies.

- Mon 31 Mar. 2014 09:04 PM Republic of Korea
www.cancerline.co.kr/html/10480.html 

Attachments
Previous Announcement: An annual general meeting of stockholders
Next MedPacto Announces Clinical Collaboration with MSD to Evaluate Vactosertib, an Investigational TGF-β Type I Receptor Inhibitor, in combination with KEYTRUDA® (pembrolizumab)